menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

A Look at Lecanemab: The Latest Breakthrough in Alzheimer’s Treatment

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Alzheimer’s disease is the most common form of dementia, and symptoms become more severe over time. In fact, it’s the leading cause of disability and poor health in older adults. And although there’s no cure, a new medication called lecanemab recently received accelerated approval by the US Food and Drug Administration. So what might this new development mean for the 6 million Americans living with this debilitating disease? Find out as Dr. Andrew Wilner speaks with fellow ReachMD host Dr. David Weisman, who’s also the Director of Clinical Research at Abington Neurological Associates.

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Alzheimer’s disease is the most common form of dementia, and symptoms become more severe over time. In fact, it’s the leading cause of disability and poor health in older adults. And although there’s no cure, a new medication called lecanemab recently received accelerated approval by the US Food and Drug Administration. So what might this new development mean for the 6 million Americans living with this debilitating disease? Find out as Dr. Andrew Wilner speaks with fellow ReachMD host Dr. David Weisman, who’s also the Director of Clinical Research at Abington Neurological Associates.

Facebook Comments

Schedule30 Sep 2023